Estradiol Articles
Warner Chilcott files patent suit over Loestrin 24 Fe
7 August 2006
Takeover costs impact Schering AG's 1st-half 2006
31 July 2006
Wyeth's revenues hit $5.2B for 1st-half 2006
31 July 2006
Takeover costs impact Schering's 1st-half 2006
26 July 2006
Final appro for Mylan's Estradiol strengths
26 July 2006
Organon's NuvaRing approved in Australia
17 July 2006
Lybrel receives an FDA approvable letter
10 July 2006
Organon starts Ph III NOMAC/E2 trials
19 June 2006
FDA warns Wyeth about Puerto Rico plant
5 June 2006
Barr's profits up 24% to $76M
15 May 2006
Schering completes EU MRP for Yasminelle
15 May 2006
Vivus' Evamist sees strong Ph III data
15 May 2006
ACOG: Strong data on Wyeth's Lybrel
15 May 2006
FDA accepts Antares' Bio-E-Gel NDA
1 May 2006
Wyeth's 1st-qtr 2006 revenues $4.8B, up 6%
1 May 2006
16% 1st-qtr 2006 sales rise for Schering AG
24 April 2006
Schering AG's Yaz gets FDA go ahead
27 March 2006
Schering AG sees 2005 net leap 23%
27 February 2006
US FDA gives tentative OK for Schering's Yaz in PMDD
30 January 2006
Schering AG's osteoperosis patch gets US go ahead
9 January 2006
Novavax receives L8.0M license payment
9 January 2006
FDA extends review of Schering's Yaz NDA
19 December 2005
Barr, Organon and Savient settle over Mircette
19 September 2005
Schering AG gets approval in the Netherlands for Yasminelle
22 August 2005
US FDA accepts NDA on Wyeth's birth-control pill
8 August 2005
Schering AG 1st-half profits leap 23%
1 August 2005
Novavax raises $4,000,000 in equity offering
11 July 2005
New Warner Chilcott posts 1st-qtr loss
11 July 2005
Schering AG opens Asia-Pacific HQ in Singapore
20 June 2005
Merck KGaA grants Organon rights
6 June 2005
1st-qtr net doubles for Akzo Nobel
25 April 2005
BioSante's Bio-E-Gel completes Phase III
18 April 2005
Antares unveils contraceptive transdermal gel
11 April 2005
Barr confirms filing in USA for Yasmin
4 April 2005
Schering AG's Yasmin under pressure in USA
28 March 2005
Solvay sees dip in 2004 pharma sales
7 March 2005
Why estrogenic hormones induce different responses in women
28 February 2005
Hope that kelp could cut breast cancer risk
21 February 2005
Warner Chilcott's low-dose femhrt approved
24 January 2005
Barr's Duramed acquires exclusive rights to Nordette
10 January 2005
Cellegy and ProStrakan in Cellegesic deal
20 December 2004
FDA approvable letter for Schering AG's Yaz
22 November 2004
Battle for Warner Chilcott may continue
8 November 2004
Schering AG's three-qtr EPS rises 12%
25 October 2004
UPDATE: Ireland's Warner Chillcott mulls L1.7 billion offer from private equity group
27 September 2004
Schering AG's Angeliq on track in USA
20 September 2004
Additional patent for Schering AG's Yasmin
20 September 2004
Barr excercises royalty option on Seasonale
20 September 2004
Stock Commentary - Europe
13 September 2004
Schering AG's Angeliq launched in Europe
6 September 2004
UPDATE: Warner Chilcott's Femtrace OKed in USA
30 August 2004
Warner Chilcott's Femtrace cleared in USA
30 August 2004
Warner Chilcott beats expectations
16 August 2004
Schering AG raises 2004 forecast on 2nd-qtr
2 August 2004
Novavax to reacquire all rights to Estrasorb
26 July 2004
Schering-AG's low-dose Yasmin delayed
26 July 2004
Letter from the Editor
21 June 2004
Schering AG's Menostar approved in the USA
14 June 2004
Galen sees 2nd-qtr 2004 EPS rocket 84%
24 May 2004
Barr's 3rd-qtr revenues rocket 87%
10 May 2004
Schering AG's 1st-qtr beats expectations
3 May 2004
Efroze launches drugs in Nigeria
3 May 2004
J&J's sales leap 17.7% for 1st-qtr 2004
19 April 2004
Barr and Galen announce Loestrin and Ovcon 35 deals
5 April 2004
Merck KGaA forecasts tough year in France
5 April 2004
AstraZeneca's Faslodex meets unmet need in breast cancer
29 March 2004
Novo Nordisk enrolls Innovex for menopause drugs sales
29 March 2004
Vivus licenses two products from Acrux
23 February 2004
Barr 2nd-qtr turnover rockets 79%
16 February 2004
FDA clears Solvay's EstroGel
16 February 2004
Schering AG's Climara Pro launched in USA
16 February 2004
UPDATE: Schering AG reports 6% "organic" sales growth for 2003, but conservative outlook
16 February 2004
Galen reports 105% leap in 1st-qtr sales
16 February 2004
Galen gains US exclusivity period for Ovcon
26 January 2004
Watson launches TriNessa oral contraceptive
5 January 2004
Barr introduces generic Tri-Cyclen
5 January 2004
Schering AG files NDA for low-dose Yasmin
22 December 2003
FDA approves new Ovcon 35
24 November 2003
BioSante starts Ph III trial for Bio-E-Gel
20 October 2003
FDA clears Novavax' estrogen therapy
20 October 2003
Barr Labs and Galen in oral contraceptives licensing deal
22 September 2003
Barr's Seasonale gets approval from FDA
15 September 2003
Pfizer tries to end Novo HRT deal
9 June 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
